Divi's Lab further added that it along with external consultants and subject matter experts, are working to address the concerns of the US-FDA and is making all efforts to fully meet the compliance requirements. "We will respond to this warning letter with a detailed plan within the stipulated time," the company said. In the import alert issued, US-FDA has exempted several products manufactured at the company's Unit-II at Visakhapatnam, Andhra Pradesh. Divi's Labs said it will continue to supply these active ingredients to meet its obligations to its customers. Earlier in a BSE filing on March 22, the company updated the bourses that the import alert by US-FDA for the products manufactured at the company's Unit-II at Visakhapatnam was issued under two clauses 66-40 and 99-32 of the FDA regulations. The agency has exempted Levetiracetam, Gabapentin, Lamotrigine, Capecitabine, Naproxen sodium, Raltegravir potassium, Atovaquone, Chloropurine, BOC core succinate and 2,4-wing active ester.